Matter of time!!
Perhaps in late August ????

DITTO!!!

At our age, (mid 80s) it acts like it has an advantage---this is her second time around---it was COVID she had all of January and all I had was a 2 day sore throat---but this shit is different and she has an asthma history which doesn't help---

His positive optimism keeps me around,,,, but if something doesn't happen soon, I will be looking up at the grass instead of down.
Spent the past month battling this Virus shit,, it is like a cement block in the lungs,,,, my wife is still fighting it, she is slowly winning though.

He sounds relevant.
Sorta over the top like our guy,,29 Psalms

OTCShotCaller
Bullish
7/24/22, 02:05 PM
$RGBP
- The SMARTEST thing to do moving forward is BUY Heavily in front of the coming Wave; a Tsunami to be exact! Don't let the past trading patterns fool you! That's history, a new chapter has begun! Set up couldn't be better Pre-FDA Fast Track Approval for our mRNA Cancer Vaccine IND that has a Billion Dollar Market Capacity within a Trillion Dollar Market. Keep in mind the key to it all is our NR2F6 Check Point Inhibitor IP that's among a new generation of Immuno-therapy we're pairing with mRNA Biotechnology. You definitely want to position yourselves ahead of the FDA approval which could happen any moment! You can bet your bottom dollar there's going to be explosive buying that will likely blow past the 52 Week High, possibly in a single trading session as Whales begin moving in! I fully expect Koos to drop a Major PR that will reveal the funding source Partnership be it a M/A, B/O, or Big Shot Investor. I plan on snapping up another 2 M shares the week and weekly moving forward!

OTCShotCaller
Bullish
7/23/22, 11:16 PM
$RGBP
2021 52 Week High of 0.08 fast approaching on 8/27/22

How many of you believe we can hit 0.08 or surpass it by then seeing that RGBP has progressed substantially since then to now, far too many elements to list.

It's my hope Dr. Koos will announce funding by 8/27. If so, it will represent the first major PR we've been waiting for and will cause a dramatic shift in our Market profile & Share Price.

The next 4 weeks are going to be interesting to say the least.

Dr. Koos is going to need no less than $100 Million to fund our IND for an mRNA Cancer Vaccine that was filed under the FDA's Fast Track Program, the same FDA status that was given to the mRNA Covid Vaccine IND from Moderna and Pfizer not long ago that went Global!

The FDA requires disclosure of the funding source to give the final approval, therefore Koos is going to need a verifiable source that has HARD CASH on hand at this level to draw down on at will.

Let's not be surprised if Eli Lilly comes "swooping in" outta nowhere to partner with us! LOL! They got their balls busted a couple of years ago due to their failed Curevac partnership over an mRNA Cancer Vaccine in early stage development that came to nothing early on due to Cureva's faulty research data. That failed partnership cost Lilly a small fortune!

Correct---
But, you might want to re-read that post---

but, in case you are on your second bottle of Cab,,,as I am,,, and it is late on a southern Arizona party night,,, here is the necessary part----

Here's an advanced shout out to the new Millionaires when we hit the 0.1 to 0.2 range! You know who you are!


Please note the absence of the zero following the decimal point---

11
OTCShotCaller
07:28 AM
$RGBP
- Holding gains reasonably well with minor sell off profit taking as expect! New base established 0.005+

All that's needed now is a major news release!

Great time to continue accumulating sub penny while it lasts which likely isn't going to be much longer!

Here's an advanced shout out to the new Millionaires when we hit the 0.1 to 0.2 range! You know who you are!

Best wishes to all!

Yes

OTCShotCaller
48m
$RGBP
Closed UP 23.4% on 66.2 M Volume holding gains and surpassing expectations! That's nearly a 300% INCREASE in Average Volume!

We just officially entered into a NEW PHASE of RGBP's transition to the Big Time!

UP FROM HERE!

Hope many of you own at least a Million Shares while you still can sub-penny!

Prior 52 week high of 0.08 on horizon rapidly approaching on 8/27 which we should easily surpass due to major transformations since then to now, especially being debt free!

Best wishes to all!

OTCShotCaller
09:29 AM
$RGBP

So here's what we have on the table to expect..ready?

1). Buy Out or Merger Acquisition (highly likely based on Koos prior 8K, 18 months ago)

2). Koos getting funding to move our mRNA Cancer Vaccine into FDA Fast track clinical trials for treating pancreatic & colon cancer

3). Oncology Pharma obtaining funding independently to move our IND for our mRNA Cancer Vaccine for pancreatic & colon cancer into clinical trials which they have development rights to.

Did I miss anything??

I would say we're positioned for some BIG CHANGES about to happen moving forward that's going to make many of you here financially wealthy but you'll need at least 1 Million Shares.

Nothing like being in the right place at the right time!

Cheers!

LOVE DAT STRONG BID SUPPORT!!!!!!!!!!!!!!!!!!!!!!

OTCShotCaller
07:54 AM
$RGBP
- I believe that a reasonable B/O offer for RGBP would be 0.25/share or $1.45 Billion based on the O/S of 4.920 Billion. Any suggestion on this? I believe that's an epic bargain based on our Disruptive Biotechnology portfolio that includes an mRNA Cancer Vaccine IP.

$RGBP today 7/19
- Time for a sit down talk to get reality into perspective. Koos is standing at "The Event Horizon" of this Company that's going to determine its future. This is a "make it or brake it" moment! All Biopharmas reach this point sometime in their development. Most if not ALL of them operate in substantial debt for extended periods typically years, and the only way any of them transition to the BIG TIME is by advancing their IP into clinical trials which we all know requires an enormous amount of capital which they don't have. The capitalization requirements for their IP to transition into clinical trials is way over their heads. The point? Koos needs enormous capital! The good news is he's done everything in his power over the past 18 months to miraculously transform RGBP into a viable B/O candidate, the final step being settling debt, for reason acquiring companies generally have an aversion toward taking on debt. IMO B/O or M/A in progress! This seems to be a foregone conclusion!
OTCShotCaller

OTCShotCaller
7/17/22, 08:30 PM
This is WHY I've previously said Koos needs a $ Billion Dollars to move ALL his active IP through all Phases of Clinical Trials. Is it making sense now as to WHY he needs a Big Pharma B/O or M/A??!! The current IND alone for his mRNA Cancer Vaccine for all 4 Phases of Clinical Trials is going to cost somewhere in the range between $80M to $160M depending on multiple factors, and this is only a rough estimate due to their being a myriad of variables.

Personally I believe it's going to cost close to $100M for his current IND alone which is a conservative estimate! Rock bottom $80M
but unlikely. The same applies to his other active IP that have not yet advanced into an FDA IND submission. The man needs very serious LONG TERM cash capital requirements and the ONLY foreseeable way that's going to happen is via a B/O or M/A, again, not only for his current IND but his several others. I discern this is WHY we haven't heard from him in some time likely due to him being in B/O negotiations.

OTCShotCaller
7/17/22, 07:07 PM
$RGBP
- For those interested, an in depth research of what new drug development cost from IP discovery (i.e. bench research) to commercialization is on a sliding scale from $43 Million to $2.9 Billion. Koos is far beyond bench research he conducted with his colleagues over the past 30+ years. The class of IP he has patents on cost anywhere from $78M to $160M to take through all 4 Phases of clinical trials, the average being about $120M
. These figures depend on multiple factors such as trial size of patient enrollment, duration of each phase, salaries of required personnel, liability insurance, and cost of the facility where the trial is conducted which can be in multiple locations, i.e. a "Multi-Center" Trial. Also the cost of clinical trials has risen significantly over the past several years. This gives you a rough idea of how much cash is required for him to advance just his current mRNA Vaccine IND into clinical trials, not including his other active IP. Thus his need for a B/O

OTCSHOTCALLER
7/17/22, 05:27 PM
As a clinical trials physician I can attest to the reality that undertaking any clinical trials venue is extremely expensive, AND extraordinarily demanding and time consuming. It requires a Multi-Million Dollar CASH Bank Roll of not less than $150 Million (low end) that can be drawn from on demand, AND an army of qualified advanced degree professionals across dozen's of levels, daily for months on end, typically years. The ONLY venues that fits this description are a Contract Research Organization (CRO) or a Big Pharma. There would be no possible way for Koos to "go it alone." Everyone also needs to understand that Oncology Pharma is NOT a CRO. They are an Intellectual Property Broker that acquires candidate drug IP development rights typically from Biopharmas like RGBP, then turns around and outsources it to a CRO for conducting clinical trials. They also resource capital to fund clinical trials they initiate to a CRO. CROs typically don't fund clinical trials.

On May 16, 2022 Regen Biopharma, Inc. (the “Company”) issued 100,000,000 common shares (“Shares”) to Coventry Enterprises LLC in satisfaction of $334,800 of convertible indebtedness. The principal balance remaining on the $1,500,000 promissory note issued to Coventry Enterprises LLC is $648,001 as of May 16,2022.

OTCShotCaller
Bullish
11:58 AM
$RGBP
Just caught a segment on CNBC by a Stock Market Analyst named Jared Holz Oppenheimer. He mentioned that Merger/Acquisitions are the future for many Biotechs. He stated this applies to ALL sizes of Biotech Acquisitions from Large Caps to Micro Caps, AND his focus of discussion was Oncology. These Merger/Acquisitions very well may contribute to a major turn around in Market conditions back toward a Bull Market for reason Innovation is a well known driver of economic growth. We're on the right track here and couldn't be in a better place at the exact right time! Those who accumulate RGBP shares NOW are soon going to find themselves living in a new zip code! Patience is key here!

OTCShotCaller
Bullish
7/4/22, 06:26 PM
$RGBP
- Here's something that needs to be said. Something is DEFINITELY going on behind the scenes with Dr Koos prolonged silence and no updates on the Fast Track IND. It's my discernment Koos is at the negotiating table with more than one suitor working out the details of either an out right cash purchase OR Merger/Acquisition. A major indicator of that is related to his PR some time ago that "several individuals" requested updates of the Company's IP. Common sense dictates that such "individuals" are either Big Pharma CEOs and/or a Start Up Pharma looking to Turn Key a portfolio of highly marketable IP from the get go foregoing decades of research. No single investor has
$160M
to shell out for putting our IND through clinical trials. This is why that IND is still sitting there with no news of it moving into trials. Not only this, it takes an enormous amount liquid cash, man power, and expertise for that to happen which apparently Oncology Pharma is lacking. All feedback welcome.

OTCShotCaller
7/2/22, 07:26 AM
$RGBP
- Just an observation based on the following: 1) there's been no communication from Koos for what is now an extended time period; 2) note debt payoff is proceeding; 3) Koos shelled out a substantial amount of cash to settle a lawsuit with the research company that had all our valuable data which is now in his possession; 4) an update of the Company's IP was requested by "numerous sources" some time ago; 5) an IND was submitted to the FDA for Fast Track authorization to enter clinical trials for an mRNA Vaccine to treat Pancreatic & Colon cancer; 6) the Canary LOI that was on the table, although it got cancelled, it evealed Koos was able to bring a suitor to the table with
$20M
; 7) Oncology Pharma apparently has done nothing to initiate clinical trials on the same IND Koos submitted to the FDA. This implies they haven't raised funding. All this seems indicative the delay is related to Koos in Buy Out/Acquisition negotiations consistent with a prior 8K some time ago. OPINION ONLY

An eye witness account from New York City, on a cold day in December, some years ago:

A little boy, about 10-years-old, was standing before a shoe store on the roadway, barefooted, peering through the window, and shivering with cold.
A lady approached the young boy and said, 'My, but you're in such deep thought staring in that window!'
'I was asking God to give me a pair of shoes,' was the boy's reply.

The lady took him by the hand, went into the store, and asked the clerk to get half a dozen pairs of socks for the boy. She then asked if he could give her a basin of water and a towel. He quickly brought them to her.
She took the little fellow to the back part of the store and, removing her gloves, knelt down, washed his little feet, and dried them with the towel.
By this time, the clerk had returned with the socks. Placing a pair upon the boy's feet, she purchased him a pair of shoes..

She tied up the remaining pairs of socks and gave them to him.. She patted him on the head and said, 'No doubt, you will be more comfortable now.'

As she turned to go, the astonished kid caught her by the hand, and looking up into her face, with tears in his eyes, asked her.

'Are you God's wife?

OTCShotCaller
Bullish
$RGBP
- Reiteration of the recent breaking news of the clinical trial that cured ALL patients of Colorectal Cancer that was covered on CNN. Keep in mind that the drug used in that clinical trial was based on a Check Point Inhibitor like the one submitted for FDA Fast Track Status by Dr. Koos to develop an mRNA Cancer Vaccine to treat both pancreatic & colon cancer!

There are presently 7 Check Point Inhibitor drugs on the market for treating cancer which are considered the "Standard of Care" choice for treatment.

We hold the Gold!

OTCShotCaller
6/14/22, 06:05 PM
$RGBP
The present Bear Market is to our advantage when you look at the BIG PICTURE!! Why?

# 1 down market means share price suppression which translates into opportunity for accumulating a greater number of shares at a lower pps that have a high market capacity

# 2 lower share price translates into greater attraction for a Buy Out offer, i.e. the buyer gets more bang for their buck in particular if the company has Disruptive Biotechnology Patents

# 3 A Merger/Acquisition is a shoe in for our NR2F6 where the Buyer doesn't have to do anything but fund the IND which is already in place at OP in San Francisco which is what all BPs prefer, i.e. out sourcing clinical trials to conserve in house expense and man power utilization. OP has a primary role in funding the IND however it's easier for the acquiring BP to supplement any funding they have and let them do the heavy lifting. This is a perfect set up for RGBP to move ahead into clinical trials in a Bear Market

OPINION ONLY

NOPE___
But if KOOS goes the "dilution" route,, for funding,,probably,, but I will no longer be around--

Looks like a big dump here at the close--??

OTCShotCaller
6/13/22, 09:51 PM
The way I see it, moving into a full Bear Market has certain advantages knowing it won't last long in the scope of historic Market Rotations; keeping in mind we've entered into the Paradigm Shift for Cancer Cure via our Check Point Inhibitor IP soon headed into clinical trials as an mRNA Vaccine, the future of Medicine we're a part of. THIS IS ONLY FOR THOSE IN IT FOR THE LONG HAUL..

1). averaging down
2). great opportunity to accumulate shares
3). lower pps means greater bargain in Buy Out negotiations
4). opportunity for cash flushed BPs to pick up Biotech on the quick to expand their portfolio & market foot print as we merge back to a Bull Market with record revenues

We're presently at the "Re-Set" point for all this to happen, i.e. the Perfect Storm for those who can see beyond present circumstances not allowing it to cloud your judgement. This requires Vision & Insight, not for the faint heart. As it's been said, nothing to fear but fear itself, the ultimate robber

OTCShotCaller
6/13/22, 05:38 PM
$RGBP
CNN reported today 6/13/22 that the S&P 500 closed in a Bear Market when the Dow fell 876 Points i.e. the end of a Bull Market run that started in March 2020. That Bull Market lasted just over 21 months. They went on to say that most Bull Markets last an average of 60 Months, and Bear Markets last an average of 19 Months. So IMO the "take-away" here is sit tight regardless of what you see, as the current Bear Market will be relatively short lived through most of 2023, then it will phase back to a Bull Market, and that's bound to happen with the explosion in biotechnology coming down the pipeline especially with the breakthrough with Check Point Inhibitors now shown to cure colon cancer by 100% with no remission, and we got that in the Bag with our current IND for an mRNA vaccine for treating colon and pancreatic cancer. So IMO we're in the right place at the right time position in front of the next Bull Market! So between now and then, manage your shares wisely!

OTCShotCaller
6/12/22, 08:03 PM
@Kreenday - Well said! The only way we're going to move forward from here is:
1). funding for the current Fast Track IND to enter clinical trials which is in the Multi Million Dollar Range (provided it's been approved by the FDA which we don't have conformation yet);
2). Merger Acquisition/Buy Out. These are the ONLY options at this point. Also there's no way possible for dilution to come anywhere close to providing the required capitalization of clinical trials which is in the $80 Million Dollar range, and this is a conservative estimate. This amount of money must come from a "Liquid Cash" source where draw down on demand can occur.

IMO, the ONLY option I see Dr. Koos has is a Buy Out/Merger Acquisition
If he comes back next time with anything other than this, such as another "deal" like the Canary-Weill proposal, that won't be a good sign. I would real that as a stall. So at this point we need to know if the FDA has approved the IND and the funding source for clinical trials

OTCShotCaller
6/9/22, 08:05 AM
$RGBP-----NEEDS A REPEAT

Take a look at the PARADE of Immuno-Oncology Check Point Inhibitors in the media!

Seven (7) FDA Approved Check Point Inhibitors have been billed as the "Standard of Care" since 2011 for treating various forms of Cancer!

The recent one currently in the news that went Global with a 100% Cure rate for colorectal cancer makes #8

youtube.com/watch?v=8Z0Gyv-...

Like I've said before the Paradigm Shift for the future of medicine has arrived AND Dr. Koos is a genius with extraordinary insight who clearly knows what time it is!

He's not about to allow his 30 years of advanced biomedical research and Disruptive Biotechnology Patents go unnoticed by filing a Fast Track IND for treating pancreatic & colon cancer via mRNA Vaccine based on our NR2F6 Check Point Inhibitor!

OTCShotCaller
6/11/22, 06:54 PM
- Yup an we are about to enter into clinical trials on that Check Point Inhibitor NR2F6 any day. It could happen on Monday! Matter if it's this week or next, one way or another, it's going to happen soon! When that happens there will be an immediate fundamental shift in the valuation of this company that will push the pps upward. The fact that Dr. Koos has submitted the IND for NR2F6 to develop an mRNA vaccine for treating pancreatic and colon cancer, means he must have completed Pre-Clinical for that to happen for reason the results of Pre-Clinical are looked at closely before granting approval to proceed to Phase

Regen BioPharma, Inc. Responds to Numerous Requests for Updates on its Intellectual Property (IP) Portfolio
via: Prnewswire


Regen Biopharma Inc0.000.00(7.23%)
Watch

Regen Biopharma IncOTC Updated Jun 8, 2022 12:47 PM
RGBP0.00
0.00 (7.23%)
11,553
Watch
7.23%
Price
1.06%
Sentiment
0.35%
Message Volume
1D
1W
1M
3M
6M
1Y
ALL
Filter by:
All
Real-Time
Cdrbo00
Bullish
12m
$RGBP
nice little end of the day bump ,
Take it !!
3


Invest in the Innovative Companies Building the Future
Tech-driven startups are transforming most sectors. Alumni Ventures helps thousands invest in portfolios of competitive, pre-IPO startups.

Sign up.
Sponsored by: Alumni Ventures
DarkKnightTrader1
16m
$RGBP
When I get paid Friday I'm buying 400,000 more shares to put me over a million. LFG !!! Hoping for buyout, like Eli Lilly maybe.
2
DigitalEye
Bullish
58m
$RGBP
higher lows baby, let’s go ????
8
CandlesINFLATED
59m
$RGBP
I need 2 million more
2
Rich1979
Bullish
12:09 PM
$RGBP
imagine the day we appear in this acquisition overview :)

en.wikipedia.org/wiki/List_...
1
6
Willwork4RGBPP
12:01 PM
$RGBP
?? ?? ?? ?? ?? ??
1
Vdiresta13
Bullish
12:01 PM
$RGBP
power hour? Been way too long…
2
Plus
bay8605
Bullish
11:52 AM
$RGBP
Some big numbers moving
13
13


The Potential of Investing in Pre-IPO Startups
Many investors choose venture to get into high-growth startups. Alumni Ventures makes it easy to own a professional VC portfolio.

Get started.
Sponsored by: Alumni Ventures
Kreenday
Bullish
11:26 AM
$RGBP
I know things are quiet right now and all yall fellow longs are locked in, I'm just adding to my list of posts that I will copy and paste for all the noobs whenever that volume comes pouring in and the wheels are in motion.. so don't judge.. lol
11
FUCancer
Bullish
10:54 AM
$RGBP
Respect is what i have for a lot of you, contributing to a strangers request.
Happy hump day!!
11
Kreenday
Bullish
10:51 AM
$RGBP

mRNA Tech= Success ??

Immuno-therapies to treat cancer =Success??

Checkpoint Inhibitors = Success??

Regens extensive IP Portfolio pertains to all of this

prnewswire.com/news-release...

Our headlining drug TCellVax has a checkpoint inhibitor utilizing mRNA tech ... A first in-class drug.

"The Company intends to combine modified mRNA technology with Regen's existing siRNA ( small interfering RNA) intellectual property targeting the NR2F6 nuclear receptor which has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator."

prnewswire.com/news-release...

Real-Time
OTCShotCaller
08:05 AM
$RGBP
- Here's what to expect NEXT! You can bet that the recent CNN Interview with Oncologist Dr. Andrea Cercek at Sloan Kettering Cancer Center in New York who conducted the clinical trials on 14 patients with colon cancer by using the check point inhibitor Monoclonal Antibody Dostarlimab with 100% remission in ALL patents within 24 weeks, immediately went GLOBAL! It's the FIRST TIME EVER in the clinical practice of Oncology worldwide! This breakthrough represents the "Paradigm Shift" I've discussed here many times that represents the Future of Medicine, and NOW it's become an astonishing reality! Being a clinical trials physician for 30 years within the Big Pharma sector, I knew this was inevitable! What's also inevitable is every Big Pharma on the planet has heard this news by now and will be racing to grab Check Point Inhibitor Patents from any Biohparmas that have them, in particular those based on mRNA Vaccine, like RGBP. Don't be surprise if Dr Koos gets a call from Eli Lilly!

OTCShotCaller
05:44 AM
$RGBP
20/20 - Check Point Inhibitors- The video on the link below is a simplified explanation of how Check Point Inhibitors work. The extraordinary historic success of the clinical trial with 100% remission of colon cancer in 14 patients discussed in the recent CNN interview by the Oncologist who conducted the study, is just the tip of the iceberg. Although that study was based on the Monoclonal Antibody Dostarlimab as the Check Point Inhibitor, mRNA vaccines unlike monoclonal antibodies, are much more resilient and versatile and can be easily manufactured to recognize protein antigens of specific cancers, essentially a custom made vaccine tailored for specific cancer antigens. This is an extraordinary advantage and it's exactly what we see with the Covid-19 mRNA vaccine that can be quickly modified to confer immunity against its sub-type variants. Fact is the mRNA Covid vaccine is based upon the science to develop mRNA vaccines for cancers. We hold the Gold!

youtube.com/watch?v=23O8rRH...


youtube.com/watch?v=23O8rRH.

https://lasvegassun.com/news/2022/jun/07/cancer-trials-unexpected-result-100-remission/

OTCShotCaller
08:13 AM
The historic results of this breakthrough in Immuno-Oncology with the Check Point Inhibitor Drug is gone vial as expected. The media is catching onto this very quickly after this CNN Interview!

lasvegassun.com/news/2022/j...

Moving forward I expect there should be several Big Pharmas or Private Investors more than willing to fund our IND for mRNA Cancer Vaccine treatment of pancreatic and colon cancer.

At this point it's a NO BRAINER!
8
OTCShotCaller
Bullish
07:58 AM
$RGBP
- Well folks it appears we've arrived! 100% PROOF Dr. Koos is on the right track with our Check-Point Inhibitor for treating Cancer!

Just out yesterday June 6, 2022, Oncologist Dr. Andrea Cercek at Memorial Sloan Kettering Cancer Center is interviewed on CNN regarding the results of a clinical trial on 14 patients with colorectal cancer treated with the Immunotherapy Drug Dostarlimab. All 14 patients had 100% disappearance of the rectal cancer within 24 weeks of treatment with little or no side effects.
youtube.com/watch?v=a0rbO3p...

Dostarlimab was developed by a Biotech by the name of Tesaro which was later bought by GlaxoSmithKline January 2019 for $5.1B. The results of the above study was published in The New England Journal of Medicine on June 5th that describes these historic results of all patents being cancer free after treatment.
beckersasc.com/gastroentero...

This is what I've mentioned here hundreds of times, i.e. we're entering into a Paradigm Shift in the Practice of Medicine.

read the articles---
do some basic dd on RGBP
find out what a "check point inhibitor " is in medicine
you will see where RGBP fits in

More good news---from our friend--
OTCShotCaller
Bullish
07:58 AM
$RGBP
- Well folks it appears we've arrived! 100% PROOF Dr. Koos is on the right track with our Check-Point Inhibitor for treating Cancer!

Just out yesterday June 6, 2022, Oncologist Dr. Andrea Cercek at Memorial Sloan Kettering Cancer Center is interviewed on CNN regarding the results of a clinical trial on 14 patients with colorectal cancer treated with the Immunotherapy Drug Dostarlimab. All 14 patients had 100% disappearance of the rectal cancer within 24 weeks of treatment with little or no side effects.
youtube.com/watch?v=a0rbO3p...

Dostarlimab was developed by a Biotech by the name of Tesaro which was later bought by GlaxoSmithKline January 2019 for $5.1B. The results of the above study was published in The New England Journal of Medicine on June 5th that describes these historic results of all patents being cancer free after treatment.
beckersasc.com/gastroentero...

This is what I've mentioned here hundreds of times, i.e. we're entering into a Paradigm Shift in the Practice of Medicine.

This is a repost---
Click on the IRL--- lasvegassun.com/news/2022/j...
https://lasvegassun.com/news/2022/jun/07/cancer-trials-unexpected-result-100-remission/


OTCShotCaller
08:13 AM
The historic results of this breakthrough in Immuno-Oncology with the Check Point Inhibitor Drug is gone vial as expected. The media is catching onto this very quickly after this CNN Interview!

lasvegassun.com/news/2022/j...

Moving forward I expect there should be several Big Pharmas or Private Investors more than willing to fund our IND for mRNA Cancer Vaccine treatment of pancreatic and colon cancer.

At this point it's a NO BRAINER!